A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
SKU: N/A
Author: Datamonitor Healthcare
Publisher: Biomedtracker
Published: 25 January 2019
Number of pages:13
Formats:PDF
Report code:TL #10108
Highlights
Description
Highlights
“I think the fact that they are in a single tablet is not the important thing, it is actually the drugs which are much more important, and then if they were to be available in a single tablet, then you would give them as a single tablet.”
“Well, it is a very good regimen with very good results. I think, clearly, bictegravir and dolutegravir are your leading integrase inhibitors. I think clearly dolutegravir, because it has been around longer, has got issues which have developed. I think clearly that will happen with bictegravir as well, though it is nice and shiny and clean at the present time.”
“It [Delstrigo] is a very interesting drug, but they have to make a decision whether they want to be the best non-nucleoside, in which case their market is limited, or a real player in the kind of naïve initial therapy switch market, but that is going to be driven for them purely by its price.
Overview
A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.